Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- PMID: 25490933
- PMCID: PMC4270138
- DOI: 10.7554/eLife.04034
Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Abstract
The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of 50 papers in the field of cancer biology published between 2010 and 2012. This Registered Report describes the proposed replication plan of key experiments from "Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion" by Straussman and colleagues, published in Nature in 2012 (Straussman et al., 2012). The key experiments being replicated in this study are from Figure 2A, C, and D (and Supplemental Figure 11) and Figure 4C (and Supplemental Figure 19) (Straussman et al., 2012). Figure 2 demonstrates resistance to drug sensitivity conferred by co-culture with some stromal cell lines and identifies the secreted factor responsible as HGF. In Figure 4, Straussman and colleagues show that blocking the HGF receptor MET abrogates HGF’s rescue of drug sensitivity. The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by eLife.
Keywords: RTK inhibitor resistance; Reproducibility Project: Cancer Biology; biochemistry; human; methodology.
Conflict of interest statement
DB: This is a Science Exchange associated lab.
RP:CB: EI, FT and JL are employed by and hold shares in Science Exchange Inc.
The other authors declare that no competing interests exist.
Comment on
-
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.Nature. 2012 Jul 26;487(7408):500-4. doi: 10.1038/nature11183. Nature. 2012. PMID: 22763439 Free PMC article.
Similar articles
-
Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors.Elife. 2014 Dec 10;3:e04037. doi: 10.7554/eLife.04037. Elife. 2014. PMID: 25490934 Free PMC article.
-
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.Nature. 2012 Jul 26;487(7408):500-4. doi: 10.1038/nature11183. Nature. 2012. PMID: 22763439 Free PMC article.
-
Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Elife. 2016 Mar 21;5:e11414. doi: 10.7554/eLife.11414. Elife. 2016. PMID: 26999821 Free PMC article.
-
The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.Melanoma Res. 2015 Dec;25(6):470-8. doi: 10.1097/CMR.0000000000000194. Melanoma Res. 2015. PMID: 26317169 Review.
-
[MET receptor inhibition: Hope against resistance to targeted therapies?].Bull Cancer. 2017 Feb;104(2):157-166. doi: 10.1016/j.bulcan.2016.10.014. Epub 2016 Nov 15. Bull Cancer. 2017. PMID: 27863726 Review. French.
Cited by
-
Targeted Therapy in Melanoma and Mechanisms of Resistance.Int J Mol Sci. 2020 Jun 27;21(13):4576. doi: 10.3390/ijms21134576. Int J Mol Sci. 2020. PMID: 32605090 Free PMC article. Review.
-
Isolation and characterization of cancer stem cells derived from human glioblastoma.Am J Cancer Res. 2021 Feb 1;11(2):441-457. eCollection 2021. Am J Cancer Res. 2021. PMID: 33575080 Free PMC article.
-
Loss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon.Mol Cancer Res. 2015 Nov;13(11):1478-86. doi: 10.1158/1541-7786.MCR-15-0224. Epub 2015 Jul 20. Mol Cancer Res. 2015. PMID: 26194191 Free PMC article.
-
A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.Int J Mol Sci. 2021 Feb 8;22(4):1709. doi: 10.3390/ijms22041709. Int J Mol Sci. 2021. PMID: 33567764 Free PMC article.
-
Pan-cancer analysis of oncogenic role of CEP55 and experiment validation in clear cell renal cell carcinoma.Sci Rep. 2024 Nov 16;14(1):28279. doi: 10.1038/s41598-024-80057-2. Sci Rep. 2024. PMID: 39550427 Free PMC article.
References
-
- Caenepeel S, Cajulis E, Kendall R, Coxon A, Hughes P. Targeting HGF-mediated resistance to vemurafenib in V600E BRAF mutant melanoma cell lines. 2013 doi: 10.1158/1538-7445.AM2013-3405. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research. Washington, DC. Cancer Res73:Abstract. - DOI
-
- Casbas-Hernandez P, D'Arcy M, Roman-Perez E, Brauer HA, McNaughton K, Miller SM, Chhetri RK, Oldenburg AL, Fleming JM, Amos KD, Makowski L, Troester MA. Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Research. 2013;15:R82. doi: 10.1186/bcr3476. - DOI - PMC - PubMed
-
- Etnyre D, Shambannagari MR, Puri N. Washington, DC: Cancer Research; 2013. Abstract 2078: Synergistic effects of c-Met and BRAF inhibitors and role of c-Met as a therapeutic target in human melanoma. AACR 104th Annual Meeting; 2013.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
